During the course of treating non-small cell lung cancer (NSCLC) with epithelial growth
factor receptor (EGFR) mutant, gefitinib resistance (GR) is unavoidable. As the environment …

Simple Summary Lung cancer treatment options vary depending on the type and stage of
the cancer. For non-small cell lung cancer (NSCLC), treatments may include surgery …

During the past two decades, significant advances have been made in the discovery and
development of targeted inhibitors aimed at improving the survival rates of cancer patients …

Introduction Current research in EGFR-mutated NSCLC focuses on the management of drug
resistance and uncommon mutations, as well as on the opportunity to extend targeted …

Background: EGFR-TKI (tyrosine kinase inhibitor) monotherapy has become the first-line
treatment option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) …

Background Tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor
(EGFR) like the third-generation TKI osimertinib have substantially improved the treatment of …

Objectives Tyrosine kinase inhibitors (TKIs) are a standard care option in patients with non-
small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. TKI …

Simple Summary Combining certain drugs that target specific proteins in cancer cells has
been found to help people with advanced non-small cell lung cancer live longer. We …

Interstitial lung disease (ILD) or pneumonitis caused by epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICI) is a major …

The mutation of tumor suppressor gene liver kinase B1 (LKB1) has a prevalence of about
20% in non–small cell lung cancer (NSCLC). LKB1‐mutant lung cancer is characterized by …